Loading
A phase 1/2 trial of CAPOX, Sintilimab, Tislelizumab in oesophageal cancer, run by AskGene Pharma, Inc., active and no longer recruiting.
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. is a phase 1/2 interventional study registered as NCT05632939 by AskGene Pharma, Inc., with 62 participants enrolled, started 2023-02-21 and due to reach its primary completion in 2025-10-31. Interventions recorded: ASKB589 +CAPOX+Sintilimab/Tislelizumab. Conditions listed: Gastric Cancer, Gastroesophageal Cancer (GC). No results are recorded here; the registry entry is the source.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.